Valuation : Alector, Inc.

Market Cap 276M 237M 223M 204M 380M 26.15B 382M 2.64B 1.02B 13.36B 1.04B 1.01B 42.53B P/E 2026 *
-2.88x
P/E 2027 * -3.54x
Enterprise Value 48.32M 41.55M 39.09M 35.67M 66.57M 4.58B 66.91M 463M 179M 2.34B 181M 178M 7.45B EV / Sales 2026 *
4.4x
EV / Sales 2027 * -0.8x
Free-Float
90.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Alector, Inc.

1 day+0.41%
1 week+2.92%
Current month+9.29%
1 month+38.76%
3 months+50.61%
6 months+23.50%
Current year+58.33%
1 week 2.33
Extreme 2.33
2.75
1 month 1.6
Extreme 1.6
2.76
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27.05
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 30/04/2013
Director of Finance/CFO 52 19/06/2025
Chief Tech/Sci/R&D Officer - 31/12/2016
Director TitleAgeSince
Director/Board Member 71 30/04/2013
Director/Board Member 72 30/09/2018
Chairman 77 12/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Controller/Auditor

-3,625 0.0032%
03/09/26 Sell

Chief Financial Officer

-29,251 0.0262%
03/09/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%+2.92%-10.51%-56.67% 276M
+2.02%+1.26%+41.37%+105.18% 69.19B
-0.41%-2.30%+33.53%+78.63% 62.97B
-1.11%+2.78%-14.86%+375.59% 27.27B
-4.92%-3.22%-3.90%-17.87% 24.78B
+0.45%+0.57%+31.49%+15.97% 25.8B
+1.12%+0.84%+24.50%-17.84% 20.11B
+6.04%+7.25%+233.25%+383.12% 18.47B
+0.33%-0.69%-6.48%+526.89% 14.88B
-2.27%+1.37%+53.01%+160.83% 14.29B
Average +0.17%+1.31%+38.14%+155.38% 27.8B
Weighted average by Cap. +0.29%+0.46%+38.64%+141.27%

Financials

2026 *2027 *
Net sales 10.98M 9.44M 8.88M 8.1M 15.12M 1.04B 15.2M 105M 40.7M 532M 41.22M 40.32M 1.69B 26.17M 22.5M 21.17M 19.32M 36.05M 2.48B 36.23M 251M 97.03M 1.27B 98.26M 96.12M 4.04B
Net income -96.86M -83.28M -78.35M -71.5M -133M -9.18B -134M -928M -359M -4.69B -364M -356M -14.94B -98.04M -84.29M -79.3M -72.37M -135M -9.29B -136M -940M -364M -4.75B -368M -360M -15.12B
Net Debt -227M -196M -184M -168M -313M -21.56B -315M -2.18B -843M -11.02B -854M -836M -35.08B -297M -255M -240M -219M -409M -28.13B -411M -2.84B -1.1B -14.38B -1.11B -1.09B -45.76B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
08/09/26 US$2.470 +0.41% 916,854
04/09/26 US$2.460 -1.99% 496,601
03/09/26 US$2.510 -7.72% 2,792,296
02/09/26 US$2.720 +13.33% 1,672,778
01/09/26 US$2.400 +6.19% 482,393
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.470USD
Average target price
3.100USD
Spread / Average Target
+25.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!